GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Price-to-Owner-Earnings

Hansoh Pharmaceutical Group Co (HKSE:03692) Price-to-Owner-Earnings

: 40.21 (As of Today)
View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-18), Hansoh Pharmaceutical Group Co's share price is HK$15.68. Hansoh Pharmaceutical Group Co's Owner Earnings per Share (TTM) ended in Dec. 2023 was HK$0.39. It's Price-to-Owner-Earnings for today is 40.21.


The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Price-to-Owner-Earnings or its related term are showing as below:

HKSE:03692' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 24.42   Med: 36.69   Max: 103.53
Current: 39.8

During the past 8 years, the highest Price-to-Owner-Earnings of Hansoh Pharmaceutical Group Co was 103.53. The lowest was 24.42. And the median was 36.69.


HKSE:03692's Price-to-Owner-Earnings is ranked worse than
68.48% of 422 companies
in the Drug Manufacturers industry
Industry Median: 26.975 vs HKSE:03692: 39.80

As of today (2024-04-18), Hansoh Pharmaceutical Group Co's share price is HK$15.68. Hansoh Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.57. Therefore, Hansoh Pharmaceutical Group Co's PE Ratio for today is 27.56.

As of today (2024-04-18), Hansoh Pharmaceutical Group Co's share price is HK$15.68. Hansoh Pharmaceutical Group Co's EPS without NRI for the trailing twelve months (TTM) ended in was HK$0.55. Therefore, Hansoh Pharmaceutical Group Co's PE Ratio without NRI for today is 28.35.

During the past 8 years, Hansoh Pharmaceutical Group Co's highest PE Ratio without NRI was 88.25. The lowest was 19.71. And the median was 35.61.


Hansoh Pharmaceutical Group Co Price-to-Owner-Earnings Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only - 84.85 43.88 37.66 -

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.88 - 37.66 - -

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Price-to-Owner-Earnings falls into.



Hansoh Pharmaceutical Group Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Hansoh Pharmaceutical Group Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=15.68/0.39
=40.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansoh Pharmaceutical Group Co  (HKSE:03692) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Hansoh Pharmaceutical Group Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines